Home News Page 62

News

NRC and AvidBiologics Progress In Development of New Antibody-drug Conjugates

Antibody-drug conjugates combine the targeting attributes of antibodies with the cancer destroying properties of drugs that are toxic to cells. Unlike chemotherapy, antibody-drug conjugates specifically seek and destroy cancer cells, with minimal impact on healthy cells.

Millennium/Takeda Exercises Commercial License Right for Fleximer Technology

Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited has exercised an option to license commercial rights for its first novel Fleximer® antibody-drug conjugate or ADC developed as part of their collaboration with Mersana Therapeutics, announced earlier this year.

ASN004 Shows Potent, Selective Antiproliferative Activity in Tumor Cell Lines

ASN004 shows strong tumor regression resulting in tumor-free animals in multiple tumor xenograft models, at well-tolerated doses.

A Chemistry Driven Approach to Uniform Antibody-drug Conjugates: New Data on Igenica’s Site-specific Linker...

Earlier today, during a plenary session of the 2015 World ADC Summit, being held October 26-29, 2014 in San Diego, California, Randall Halcomb, PhD, Vice President Chemistry at Igenica Biotherapeutics, presented new data utilizing the company's SNAP site-specific ADC linker technology.

Sutro Biopharma and Celgene Expand Immuno-Oncology Product Discovery and Development Program

Sutro Biopharma, located in South San Francisco, and Celgene have entered into a strategic collaboration and option agreement designed...

Average DAR and DAR Distribution Assessment: The Analytical Potential of Native Mass Spectrometry and...

Antibody drug conjugates or ADCs are macromolecules which include cytotoxic drugs covalently attached via a conditionally stable linker to monoclonal antibodies...

Lilly and Zymeworks Expand Strategic Licensing and Collaboration – Broad Bi-Specific Antibody Development Now...

Originally announced in January 2014, a global strategic collaboration between Eli Lilly and Company and Zymeworks Inc. focused on...

Biotech Companies Agree To Co-Discover And Co-Develop Antibody-based Immunotherapies

PhosImmune Inc, based in Charlottesville, Virginia, USA . and PureMHC LLC, a platform technology company with expertise in disease-specific...

Study Shows Trastuzumab Emtansine is Well Tolerated by Japanese HER2-positive Metastatic Breast Cancer Patients

Ado-trastuzumab emtansine (Kadcyla®/T-DM1 Genentech/Roche), an antibody-drug conjugate composed of the cytotoxic agent DM1 conjugated to trastuzumab via a stable...

Efficacy of the Antibody-drug Conjugate PSMA-ADC in Patient-derived Prostate Cancer Xenografts

The prostate-specific membrane antigen (PSMA) is expressed in advanced prostate cancer and targeting this protein is used for imaging...